Data from Novartis AG's pivotal EXPAND study of its Gilenya follow-up siponimod (BAF312), which suggest it could be the first potential therapy to meaningfully delay disability progression in typical secondary progressive multiple sclerosis (SPMS) patients, have been published in The Lancet but experts in an accompanying commentary have questioned the extent of its efficacy.
The data from EXPAND were first presented at the September 2016 ECTRIMS meeting and showed that siponimod reduced the risk of disability progression with a safety profile similar to that of other
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?